Sangamo Therapeutics Inc expected to post a loss of 13 cents a share - Earnings Preview

Sangamo Therapeutics

09/05/2025 21:29

Sangamo Therapeutics Inc SGMO.OQ SGMO.O is expected to show a rise in quarterly revenue when it reports  results on May 12 for the period ending March 31 2025

The Richmond California California-based  company is expected to report a 1,441.9% increase in revenue to $7.417 million from $481 thousand a year ago, according to the mean estimate from 6 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Sangamo Therapeutics Inc is for a loss of 13 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Sangamo Therapeutics Inc is $3.50​, above​ its last closing price of $0.72. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.08
-0.09
-0.11
Missed
-20.5
Sep. 30 2024
-0.06
-0.03
0.04
Beat
240
Jun. 30 2024
-0.15
-0.15
-0.18
Missed
-23.5​
Mar. 31 2024
-0.22
-0.21
-0.27
Missed
-26.3
​​Dec. 31 2023
-0.26
-0.34
Missed
-32.7
Sep. 30 2023
-0.31
-0.32
-0.59
Missed
-84.4​
Jun. 30 2023
-0.35
-0.34
-0.66
Missed
-92.7
Mar. 31 2023
-0.32
-0.33
0.12
Beat
136.6

This summary was machine generated May 9 at 20:29 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)